E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers Z > Headlines for Zim Laboratories Ltd. > News item
Published on 4/9/2019 in the Prospect News Emerging Markets Daily.

India’s Zim Laboratories board OKs Rs. 350 million debentures

By Sarah Lizee

Olympia, Wash., April 9 – Zim Laboratories Ltd. informed the Bombay Stock Exchange that its board of directors approved an allotment of Rs. 350 million secured redeemable nonconvertible debentures to UTI Structured Debt Opportunities Fund I.

The allotment was approved at a meeting held Tuesday, according to a notice.

Nagpur, India-based Zim Laboratories manufactures, markets and sells formulation drugs and pre-formulation ingredients.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.